TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06613360: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

Sponsor: Cullinan Therapeutics Inc. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 24 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$1,806,420

Rescue Site Savings

+$1,196,460

Unlock Full NCT06613360 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06613360 Rescue Dossier →